Immunic AG | WebDisclosure

PRESS RELEASE

published on 11/13/2024 at 12:30, 1 year 10 months ago

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
Immunic announces publication of phase 1/1b clinical trial data of IMU-856 in The Lancet Gastroenterology & Hepatology. Positive results in celiac disease patients. Potential new approach for gastrointestinal diseases

Gastrointestinal Diseases Clinical Trial Immunic IMU-856 Celiac Disease
BRIEF

published on 11/07/2024 at 12:35, 1 year 11 months ago

Immunic, Inc. Reports Q3 2024 Financial Results

Financial Results Vidofludimus Calcium Phase 3 ENSURE Trials Multiple Sclerosis Research Clinical Trial Updates
BRIEF

published on 11/07/2024 at 12:35, 1 year 11 months ago

Immunic, Inc. publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Vidofludimus Calcique Essais ENSURE De Phase 3 Recherche Sur La Sclérose En Plaques Mises À Jour Des Essais Cliniques
PRESS RELEASE

published on 11/07/2024 at 12:30, 1 year 11 months ago

Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Immunic, Inc. reports Q3 2024 financial results, positive Phase 3 ENSURE Program interim analysis. Twin Phase 3 ENSURE trials and Phase 2 CALLIPER trial on track. Webcast held on Nov 7. IMUX stock update

Financial Results Immunic Inc. Q3 2024 Phase 3 ENSURE Program IMUX Stock
BRIEF

published on 10/31/2024 at 11:35, 1 year 11 months ago

Immunic, Inc. to Release Q3 2024 Financial Results and Corporate Update

Financial Results Biotechnology Clinical Trials Webcast Immunic
BRIEF

published on 10/31/2024 at 11:35, 1 year 11 months ago

Immunic, Inc. publiera ses résultats financiers du troisième trimestre 2024 et une mise à jour de l'entreprise

Résultats Financiers Biotechnologie Webcast Essais Cliniques Immunique
PRESS RELEASE

published on 10/31/2024 at 11:30, 1 year 11 months ago

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
Immunic, Inc. (Nasdaq: IMUX) to release Q3 financial results and corporate update on Nov 7, 2024. Webcast at 8:00 am ET. Company developing therapies for inflammatory and autoimmune diseases. Visit www.imux.com for more info

Financial Results Biotechnology Corporate Update Immunic Inc. Clinical Pipeline
BRIEF

published on 10/29/2024 at 11:35, 1 year 11 months ago

Immunic to Participate in Key Conferences Throughout November

Investors Biotechnology Clinical Trials Conférences Immunic
BRIEF

published on 10/29/2024 at 11:35, 1 year 11 months ago

Immunic participera à des conférences clés tout au long du mois de novembre

Biotechnologie Conférences Investisseurs Essais Cliniques Immunique
PRESS RELEASE

published on 10/29/2024 at 11:30, 1 year 11 months ago

Immunic to Participate in Industry, Scientific and Investor Conferences in November
Immunic to participate in industry, scientific, and investor conferences in November 2024, presenting data on IMU-856 for celiac disease. Details on events and presentations available on company website

Clinical Trials Conférences Investor Immunic Scientific

Published on 10/10/2026 at 04:45, 13 hours 43 minutes ago

Immutable Holdings and Jorge Masvidal's Gamebred Fighting Championship (FC) Enter Into Definitive Agreement for Proposed Reverse Takeover Transaction and Listing on the TSXV
Published on 10/10/2026 at 02:03, 16 hours 25 minutes ago

BrandPilot AI Announces Closing of Previously Announced Debt Settlement
Published on 10/10/2026 at 02:00, 16 hours 28 minutes ago

Battery X Metals Reports Estimated Driving Range Increase of Approximately 101 Kilometers Following a Single-Electric-Vehicle Performance Evaluation of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Technology
Published on 10/09/2026 at 23:00, 19 hours 28 minutes ago

Trans Canada Gold Closes First Tranche of Non-Brokered Private Placement for Gross Proceeds of CDN $2,144,720
Published on 10/09/2026 at 22:15, 20 hours 13 minutes ago

Loop Industries to Host Second Quarter Fiscal 2027 Earnings Conference Call

View all ACCESSWIRE

Published on 10/10/2026 at 16:35, 1 hour 53 minutes ago

New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
Published on 10/10/2026 at 16:30, 1 hour 58 minutes ago

ZPMC-Built Infrastructure Supports China's First Offshore Wind Project to Deploy 18 MW Turbines at Scale
Published on 10/10/2026 at 10:05, 8 hours 23 minutes ago

ONLYOFFICE 10.0 brings AI tools, modular apps, and stronger security to its open-source office suite
Published on 10/09/2026 at 21:24, 21 hours 3 minutes ago

Branicks Group AG: Extraordinary General Meeting does not approve all items on the agenda
Published on 10/09/2026 at 21:17, 21 hours 10 minutes ago

EQS-Adhoc: Branicks Group AG: Agenda topic four at extraordinary general meeting rejected

View all EQS

Published on 10/09/2026 at 19:27, 23 hours 1 minute ago

Disclosure of transactions in own shares from October 1 to October 9, 2026
Published on 10/09/2026 at 19:27, 23 hours 1 minute ago

Déclaration hebdomadaire d'opérations effectuées du 1er au 9 octobre 2026
Published on 10/09/2026 at 18:01, 1 day ago

Titre de mon communiqué
Published on 10/09/2026 at 18:01, 1 day ago

Title of my press release
Published on 10/09/2026 at 17:45, 1 day ago

Déclaration des droits de vote à fin septembre 2026

View all LES ECHOS COMFI WIRE

News